Core Viewpoint - The company reported a significant revenue increase of 75.4% year-on-year, reaching 294 million RMB, while narrowing its net loss by 12.6% to 132 million RMB, indicating improved financial performance and operational efficiency [1] Financial Performance - Revenue for the six months ending June 30, 2025, was 294 million RMB, reflecting a year-on-year growth of 75.4% [1] - The net loss was 132 million RMB, which is a 12.6% reduction compared to the previous year [1] - Basic loss per share was 0.17 RMB [1] Product Development and Approvals - The company has successfully commercialized multiple products sourced from Alcon, enhancing its product line and market opportunities [1] - Research and development expenses were 39 million RMB, showing a decrease of 33.6% year-on-year, indicating cost management efforts [1] - The product OT-703 (ILUVIEN) has been approved for real-world research application in Hainan Boao Lecheng International Medical Tourism Pilot Zone [1] - The product OT-802 (a treatment for presbyopia) has received CDE approval for its Phase III clinical trial, highlighting its potential to fill a market gap in China [1] - Six products have received production approval during the reporting period, and the commercialization process is progressing smoothly [1]

智通财经APP讯，欧康维视生物-B(01477)发布截至2025年6月30日止六个月业绩，收入2.94亿元(人民 币，下同)，同比增长75.4%;净亏损1.32亿元，同比收窄12.6%;每股基本亏损0.17元。 期内，多款核心产品增长稳定，公司从Alcon引进的多款商业化产品对接顺利，为公司带来增量业务， 产品线厚度提升，市场空间打开;公司研发费用支出3900万元，同比减少33.6%，在研管线稳步推进，多 款产品均取得较快进展。 智维泰 (0.24%西替利嗪滴眼液)获NMPA批准商业化，是目前唯一获FDA批准可以用于两岁及以上患者 的抗过敏眼科药物。 OT-703(ILUVIEN，氟轻松玻璃体植入剂)获CDE批准纳入海南博鰲乐城国际医疗旅游先行区药品真实世 界研究应用试点品种，并已开始进行真实世界研究患者入组工作。 集团针对老视适应症的自主研发产品OT-802(盐酸毛果蕓香硷)III期临床试验申请已获CDE批准，显示出 其有潜力填补中国目前老视领域商业化创新药物市场的空白。 报告期内，集团的六款产品已获生产批准。集团产品的商业化批次生产有序进行中，优施莹的本地化生 产工作进入到审评公示阶段。 ...